Physician profile
Jane C Lanier
NPI 1336435262
$2,619.60
in general payments reported to CMS, 2019-2025
22 companies · $731 in 2025
The $731 reported for 2025 was more than what 81% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.72 · 2021: $48.47 · 2022: $436 · 2023: $631 · 2024: $755 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021 · Education: $96.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.57 |
| Education | $96.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $453.57 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $282.74 | 2022-2025 | Caplyta |
| Corium, LLC | $198.06 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $193.31 | 2020-2025 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $172.67 | 2024-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $171.91 | 2022-2024 | Austedo Xr |
| Tris Pharma INC | $166.48 | 2023-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $134.34 | 2023-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $114.07 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $109.29 | 2022-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $96.54 | 2023-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $91.19 | 2025 | Jornay Pm |
| Lundbeck LLC | $84.66 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $64.58 | 2021-2023 | Hetlioz |
| Abbvie INC. | $59.24 | 2023-2025 | Vraylar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $47.87 | 2022-2023 | Auvelity |
| Neos Therapeutics, LP | $41.66 | 2023-2024 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $39.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $36.60 | 2023 | Quviviq |
| Tempus Ai, INC | $24.04 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $20.88 | 2025 | Cobenfy |
| Alfasigma USA, INC. | $16.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.